Clinical trials
Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials
Below are recruiting pancreatic ductal adenocarcinoma (pdac) clinical trials, each written for real people, not researchers. We’re tracking 144 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06320717Recruiting
AI-guided pre-surgery treatment for pancreatic cancer
This study tests how well an AI tool can guide which pre-surgery treatment is best for people with pancreatic cancer that can be removed. It uses your tumor's genetic fingerprint to choose the most effective therapy.
Buffalo, New YorkAges 18 years+ - NCT07047807Recruiting
Digital support app for pancreatic cancer patients starting treatment
This trial tests a smartphone app designed to provide information and support to people with pancreatic cancer who are about to start neoadjuvant therapy before surgery. The app aims to help you manage your care and feel more supported during this time.
Boston, MassachusettsAges 18 years+ - NCT07241676Enrolling by invitation
Pancreatic cancer surgery and early recurrence study
This study looks at patients who had surgery to remove pancreatic cancer to understand what factors might lead to the cancer coming back early. If you have had surgery for pancreatic cancer and are interested in helping researchers learn more, this may be a fit.
Padova, PDAges 18 years+ - NCT07155850Recruiting
Testing YntraDose before chemotherapy for advanced pancreas cancer
This trial tests a new treatment called YntraDose, given directly into the pancreas tumor before standard chemotherapy. It is for people with locally advanced pancreatic cancer that cannot be removed by surgery.
RomaAges 18 years+ - NCT07165951RecruitingPhase 3
Study of new drug combo for first treatment of advanced pancreatic cancer
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
Hefei, AnhuiAges 18–75 - NCT07483983RecruitingPhase 2
Study of ASP3082 for advanced lung and pancreatic cancers with KRAS G12D mutation
This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.
Villejuif, FranceAges 18 years+ - NCT07252232RecruitingPhase 3
A pill to prevent pancreatic cancer recurrence after surgery
This trial tests an experimental daily pill, daraxonrasib, in people with pancreatic cancer that has been surgically removed. It’s for those who also had chemotherapy and have a specific DNA change called a RAS mutation. The goal is to see if the pill helps prevent the cancer from coming back.
Phoenix, ArizonaAges 18 years+ - NCT07255404RecruitingPhase 2
Testing pumitamig with chemotherapy for untreated pancreatic cancer
This trial tests an experimental drug called pumitamig combined with standard chemotherapy for people with advanced pancreatic cancer that has spread and has not been treated yet. The goal is to see if this combination is safe and effective.
Bedford ParkAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Chuo Ku, TokyoAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Phoenix, ArizonaAges 18 years+ - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT06937177RecruitingPhase 2
Testing mifomelatide to help maintain weight during chemo
This trial tests an investigational drug called mifomelatide (TCMCB07) to see if it can help people with newly diagnosed colorectal or pancreatic cancer maintain a healthy weight while receiving certain types of chemotherapy. You would give yourself a daily injection under the skin.
Tucson, ArizonaAges 18 years+ - NCT07702292RecruitingPhase 2
68Ga-BED003 PET scan for certain cancers
This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.
Bergamo, LombardyAges 18–79 - NCT03977233RecruitingPhase 2
Biopsies and FOLFIRINOX for non-metastatic pancreatic cancer
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
Chapel Hill, North CarolinaAges 18–99 - NCT04005690RecruitingEarly Phase 1
Targeted drug treatment for pancreatic cancer using pathway changes
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Portland, OregonAges 18 years+ - NCT04622423Recruiting
Advanced therapies for colon or pancreas liver metastases
This study tests advanced treatments for cancer that has spread to the liver, either from colon cancer or pancreatic cancer. It may help by targeting liver tumors using treatment plans and, for some participants, liver tissue samples.
Milan, MilanAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT05132244Recruiting
Checking and treating blood sugar in pancreatic cancer
This trial tests a plan to monitor and manage blood sugar in people with pancreatic ductal cancer who are starting a specific chemotherapy regimen (FOLFIRINOX). The goal is to prevent or address high blood sugar during treatment, which may help people stay on therapy safely.
Vancouver, British ColumbiaAges 18 years+ - NCT05218889RecruitingPhase 1/Phase 2
Surufatinib plus immunotherapy for advanced pancreatic cancer
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
BeijingAges 18–75 - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Orange, CaliforniaAges 18 years+ - NCT05526443Recruiting
Registry study for advanced pancreatic cancer treatment patterns
This registry collects information about people with advanced pancreatic cancer who are receiving first-line palliative treatment. It helps doctors understand which treatment choices are used and how people do over time.
Graz, StyriaAges 18 years+ - NCT05723107RecruitingPhase 1
Testing an endoscopic treatment for pancreatic cancer that can't be removed
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
New York, New YorkAges 18 years+ - NCT05727020Recruiting
Breath test study for pancreatic cancer and related conditions
This study checks whether breathing out certain chemicals (volatile organic compounds) can help identify pancreatic ductal adenocarcinoma (pancreatic cancer) or related pancreas problems. You may qualify if you’re an adult with suspected/confirmed pancreatic conditions and can safely take part in breath testing or surgery-related tissue collection.
LondonAges 18 years+ - NCT05968326RecruitingPhase 2
Chemo plus new vaccines versus chemo alone after pancreatic surgery
This Phase 2 trial tests whether adding two study medicines (an immune-based vaccine treatment plus atezolizumab) to standard chemo helps prevent pancreatic cancer from coming back after surgery. It compares the combination against standard chemo alone, looking at safety and how well it prevents relapse.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic ductal adenocarcinoma (pdac)?
- Yes. Clin2 currently lists 144 recruiting pancreatic ductal adenocarcinoma (pdac) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic ductal adenocarcinoma (pdac) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic ductal adenocarcinoma (pdac) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (mPDAC)
- Resectable Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Unresectable Pancreatic Ductal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.